Latest Us Regulatory News

Page 1 of 9
The US FDA has refused to lift the clinical hold on Argenica Therapeutics’ xaranetide stroke program, demanding a GLP rat neurotoxicity study and imposing a lower exposure limit than the company proposed for Phase 2b. Argenica plans to challenge parts of the assessment while pursuing regulatory submissions elsewhere.
Ada Torres
Ada Torres
19 Nov 2026
Marine Biomedical has secured US FDA 510(k) clearance for PearlBone, giving Orthocell a clearer path into bone regeneration through its 12% strategic stake and distribution rights. The commercial opportunity is advancing, but revenue, launch timing and definitive distribution arrangements remain undisclosed.
Ada Torres
Ada Torres
3 Nov 2026
Nexsen has secured ISO 13485 certification covering the design, development and manufacture of its StrepSure Group B Streptococcus diagnostic. The milestone strengthens the product’s regulatory and manufacturing platform, but does not yet amount to FDA or TGA approval.
Ada Torres
Ada Torres
2 Nov 2026
American Tungsten & Antimony has completed its Nexus acquisition and secured ownership of the Del Sol hydrometallurgical refinery in Nevada, moving its US antimony strategy from transaction to execution. The Arizona White Spar acquisition remains conditional, while the completion consideration includes more than one billion shares and substantial performance rights.
Victor Sage
Victor Sage
30 Oct 2026
Vectus Biosystems has secured FDA acceptance of a pre-IND Type B meeting for VB0004, a key regulatory step for its idiopathic pulmonary fibrosis programme. The biotech ended September with $410,000 in cash and reported estimated funding for just 1.33 quarters of operations.
Ada Torres
Ada Torres
29 Oct 2026
BlinkLab has reported 82% sensitivity and 83% specificity from an exploratory ADHD study in 208 children, while preparing a US regulatory program for a second product. Its autism diagnostic remains on track for pivotal study completion this quarter, with A$16.2 million in cash at 30 September.
Victor Sage
Victor Sage
29 Oct 2026
Neurotech International has dosed the first patient in its pivotal Phase 3 trial of NTI164, with all six Australian sites now active and up to 200 children planned for enrolment. The milestone sits alongside FDA clearance and fresh funding, but quarter-end cash covered only 1.24 quarters of historical operating outflows.
Ada Torres
Ada Torres
28 Oct 2026
Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.
Ada Torres
Ada Torres
28 Oct 2026
Vitrafy has expanded its US blood and cell therapy partnerships while preparing Guardion for a planned medical device listing by the end of 2026. The company ended September with A$38.3 million in cash and term deposits, but expects spending to rise as validation and manufacturing accelerate.
Victor Sage
Victor Sage
28 Oct 2026
OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.
Victor Sage
Victor Sage
27 Oct 2026
Clarity Pharmaceuticals has completed planned recruitment for its 383-participant CLARIFY Phase III trial of 64Cu-SAR-bisPSMA, moving the diagnostic candidate into patient follow-up. Topline sensitivity and specificity data are expected in the first half of 2027 and could support a US FDA application.
Ada Torres
Ada Torres
27 Oct 2026
Nyrada has moved its PROTECT-MI heart-attack trial into active recruitment, with four hospitals open and three patients dosed. The biotech also reported supportive US FDA feedback, encouraging preclinical oncology data and AU$13.72 million in cash after a AU$12 million placement.
Ada Torres
Ada Torres
19 Oct 2026

Browse the archive

Full archive